Lys103
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.1.1
Powered by Cell Signaling Technology
Home > Sumoylation Site Page: > Lys103  -  TOP1 (human)

Site Information
ASGDAKIkKEKENGF   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 2793908

In vivo Characterization
Methods used to characterize site in vivo:
electrophoretic mobility shift ( 2 ) , immunoassay ( 3 ) , mutation of modification site ( 2 , 3 ) , western blotting ( 2 , 3 )
Disease tissue studied:
bone cancer ( 2 ) , colorectal carcinoma ( 3 )
Relevant cell line - cell type - tissue:
293 (epithelial) ( 3 ) , CHO (fibroblast) ( 3 ) , HeLa (cervical) ( 3 ) , KM12 (intestinal) ( 3 ) , U2OS (bone cell) ( 2 )

Upstream Regulation
Treatments:
CPT ( 2 )

Downstream Regulation
Effects of modification on TOP1:
intracellular localization ( 3 )

References 

1

Lumpkin RJ, et al. (2017) Site-specific identification and quantitation of endogenous SUMO modifications under native conditions. Nat Commun 8, 1171
29079793   Curated Info

2

Hammer E, Heilbronn R, Weger S (2007) The E3 ligase Topors induces the accumulation of polysumoylated forms of DNA topoisomerase I in vitro and in vivo. FEBS Lett 581, 5418-24
17976381   Curated Info

3

Rallabhandi P, et al. (2002) Sumoylation of topoisomerase I is involved in its partitioning between nucleoli and nucleoplasm and its clearing from nucleoli in response to camptothecin. J Biol Chem 277, 40020-6
12149243   Curated Info

Developed with grants from  NIH Logo and literature mining with Linguamatics  I2E Logo Creative Commons License PhosphoSite, created by Cell Signaling Technology is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.

©2003-2019 Cell Signaling Technology, Inc.